Hydroxocobalamin monohydrochloride 盐酸羟钴胺; Vitamin B12a monohydrochloride|cas:59461-30-2|西域试剂

Hydroxocobalamin monohydrochloride 盐酸羟钴胺; Vitamin B12a monohydrochloride,98.0%

产品编号：Bellancom-B2209A| CAS NO：59461-30-2| 分子式：C₆₂H₉₀ClCoN₁₃O₁₅P| 分子量：1382.82

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-B2209A	￥600.00	杭州北京（现货）
Bellancom-B2209A	￥1450.00	杭州北京（现货）
Bellancom-B2209A	￥2250.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Hydroxocobalamin monohydrochloride 盐酸羟钴胺; Vitamin B12a monohydrochloride

产品介绍

Hydroxocobalamin monohydrochloride (Vitamin B12a monohydrochloride) 是一种可注射的天然维生素 B12，具有良好的不良反应特征，可作为维生素 B12 缺乏症 (包括恶性贫血) 的膳食补充剂。

生物活性

Hydroxocobalamin monohydrochloride (Vitamin B12a monohydrochloride) is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the treatment of vitamin B12 deficiency including pernicious anemia.

体外研究

The cobalt atom of hydroxocobalamin binds cyanide and nitric oxide and hydroxocobalamin attenuates vascular responses to NO in vitro.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Treatment with hydroxocobalamin before or after giving LPS attenuates LPS-induced hypotension and increases in plasma RNI and enhances LPS-induced urinary excretion of RNI. Hydroxocobalamin (20 mg/kg i.p.) given to Swiss-Webster mice 30 min before giving LPS (16 mg/kg i.p.) decreases the 24-hr mortality of LPS from 80 to 50% and the 36- and 96-hr mortality from 100 to 60% (hydroxocobalamin).
More than 60% of the mice administered 35 mg/kg (0.63 mmol/kg) of NaSH (LD90) survive (at 24 h) when hydroxocobalamin (0.25 mmol/kg) is given after NaSH administration whereas less than 15% of the mice survive without hydroxocobalamin. Hydroxocobalamin (50–100 μM) or cobalt (50–100 μM) also preventes hepatocyte cytotoxicity induced by NaSH (500 μM). Furthermore, adding hydroxocobalamin 60 min later than NaSH still shows some protective activity^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (72.32 mM; Need ultrasonic)

H₂O : 25 mg/mL (18.08 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.7232 mL	3.6158 mL	7.2316 mL
5 mM	0.1446 mL	0.7232 mL	1.4463 mL
10 mM	0.0723 mL	0.3616 mL	0.7232 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 50 mg/mL (36.16 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (1.81 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (1.81 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (1.81 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (1.81 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明